Resultats globals: 7 registres trobats en 0.03 segons.
Articles, 7 registres trobats
Articles 7 registres trobats  
1.
9 p, 267.2 KB A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis : results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP) / Reich, K. (SCIderm GmbH) ; Zschocke, I. (SCIderm GmbH) ; Bachelez, Hervé (AP-HP Hôpital Saint-Louis) ; de Jong, E.M.G.J. (Radboud University Medical Centre and Radboud University) ; Gisondi, Paolo (University of Verona) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Warren, R. B. (Manchester Academic Health Science Centre) ; Ortland, C. (Das Forschungsdock Service for Clinical Development) ; Mrowietz, Ulrich (University Medical Center Schleswig-Holstein) ; Universitat Autònoma de Barcelona
Around two-thirds of patients with psoriasis do not adhere to topical treatment. The Topical Treatment Optimization Programme (TTOP), a five-element tool, includes guidance for the conversation between dermatologists/nurses and patients, patient information material, telephone/e-mail helpdesks and treatment reminders. [...]
2017 - 10.1111/bjd.15466
British journal of dermatology, Vol. 177 Núm. 1 (july 2017) , p. 197-205  
2.
7 p, 283.2 KB A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features : results from psoriasis patients in Spain / Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; van de Kerkhof, P. C. M. (Radboud University Nijmegen Medical Centre) ; Reich, K. (Sclderm Research Institute and Dermatologikum Hamburg) ; Bachelez, Hervé (Sorbonne Paris Cité Université Paris Diderot) ; Barker, J.N (King's College London) ; Girolomoni, G. (University of Verona) ; Paul, C. (Paul Sabatier University and Larrey Hospital) ; Universitat Autònoma de Barcelona
The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed to account for cultural and healthcare system differences across European countries (EC). To utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment and Dermatology Life Quality Index (DLQI). [...]
2017 - 10.1111/jdv.14195
Journal of the European Academy of Dermatology and Venereology, Vol. 31 Núm. 7 (july 2017) , p. 1176-1182  
3.
8 p, 789.9 KB Long-term efficacy and safety of brodalumab in the treatment of psoriasis : 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial / Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Lebwohl, M. (Icahn School of Medicine at Mount Sinai) ; Bachelez, Hervé (AP-HP Hôpital Saint-Louis) ; Sobell, J. (SkinCare Physicians) ; Jacobson, A.A. (Ortho Dermatologics) ; Universitat Autònoma de Barcelona
Randomized controlled trials have shown the efficacy and safety of brodalumab in patients with moderate to severe plaque psoriasis. To evaluate the efficacy and safety of brodalumab through 120 weeks of treatment in the AMAGINE-2 trial. [...]
2020 - 10.1016/j.jaad.2019.05.095
Journal of the American Academy of Dermatology, Vol. 82 Núm. 2 (february 2020) , p. 352-359  
4.
3 p, 1.3 MB Vaccine hesitancy and access to psoriasis care during the -19 pandemic : findings from a global patient-reported cross-sectional survey / Bechman, Katie (King's College London) ; Cook, Emma S. (King's College London) ; Dand, Nick (Health Data Research UK) ; Yiu, Zenas Z.N. (The University of Manchester) ; Tsakok, Teresa (King's College London) ; Meynell, Freya (King's College London) ; Coker, Bolaji (King's College London) ; Vincent, Alexandra (King's College London) ; Bachelez, Hervé (Université de Paris) ; Barbosa, Ines (King's College London) ; Brown, Matthew A. (King's College London) ; Capon, Francesca (King's College London) ; Contreras, Claudia R. (Universidad Nacional de Asuncion) ; De La Cruz, Claudia (Clinica Dermacross) ; Di Meglio, Paola (King's College London) ; Gisondi, Paolo (University of Verona) ; Jullien, Denis (Groupe de recherche sur le psoriasis (GrPso) de la Société Française de dermatologie) ; Kelly, Jade (NIHR Manchester Biomedical Research Centre) ; Lambert, Jo (Ghent University) ; Lancelot, Camille (International Federation of Psoriasis Associations) ; Langan, Sinead M. (London School of Hygiene and Tropical Medicine) ; Mason, Kayleigh J. (Keele University) ; McAteer, Helen (The Psoriasis Association) ; Moorhead, Lucy (King's College London) ; Naldi, Luigi (Centro Studi GISED) ; Norton, Sam (King's College London) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Spuls, Phyllis I. (Amsterdam UMC. University Medical Center) ; Torres, Tiago (Centro Hospitalar do Porto) ; Urmston, Dominic (The Psoriasis Association) ; Vesty, Amber (The Psoriasis Association) ; Warren, Richard B. (NIHR Manchester Biomedical Research Centre) ; Waweru, Hoseah (International Federation of Psoriasis Associations) ; Weinman, John (King's College London) ; Griffiths, Christopher E.M. (NIHR Manchester Biomedical Research Centre) ; Barker, Jonathan (King's College London) ; Smith, Catherine H. (King's College London) ; Galloway, James B. (King's College London) ; Mahil, Satveer K. (King's College London) ; Universitat Autònoma de Barcelona
2022 - 10.1111/bjd.21042
British journal of dermatology, Vol. 187 (may 2022) , p. 254-256  
5.
11 p, 652.6 KB Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type : a cross-sectional patient survey* / Mahil, Satveer K. ; Yates, Mark (King's College London) ; Langan, Sinead M. (London School of Hygiene and Tropical Medicine) ; Yiu, Zenas Z.N. ; Tsakok, Teresa ; Dand, Nick ; Mason, Kayleigh J. ; McAteer, Helen ; Meynell, Freya ; Coker, Bolaji ; Vincent, A. (Guy's and St Thomas' NHS Foundation Trust) ; Urmston, Dominic ; Vesty, Amber ; Kelly, J. (The University of Manchester) ; Lancelot, Camille (France Veterinary International) ; Moorhead, Lucy (Guy's and St Thomas' NHS Foundation Trust) ; Bachelez, Hervé (Université Paris Cité) ; Bruce, I.N. (The University of Manchester) ; Capon, Francesca (King's College London) ; Contreras, Claudia Romina (Universidad Nacional de Asunción) ; Cope, Andrew P. (Kingston College United Kingdom) ; De La Cruz, C. (University of Santiago, Chile) ; Di Meglio, Paola (Newcastle University) ; Gisondi, Paolo (University of Verona) ; Hyrich, Kimme (The University of Manchester) ; Jullien, Denis (Hospices Civils de Lyon (Centre Hospitalier Universitaire de Lyon)) ; Lambert, Julien ; Marzo-Ortega, H. (Leeds Teaching Hospitals NHS Trust) ; McInnes, Iain B. (University of Glasgow) ; Naldi, L. (San Bortolo Hospital) ; Norton, Sam (King's College London) ; Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ; Sengupta, Raj (Royal National Hospital For Rheumatic Diseases NHS Foundation Trust) ; Spuls, Phyllis (University of Amsterdam) ; Torres, Tiago (Centro Hospitalar e Universitário do Porto) ; Warren, Richard B. (The University of Manchester) ; Waweru, Hoseah (Upper Hill Medical Centre) ; Weinman, John (King's College London) ; Griffiths, Chris E.M. (The University of Manchester) ; Barker, Jonathan (The Kings College) ; Brown, Matthew A. (Guy's and St Thomas' NHS Foundation Trust) ; Galloway, James B. ; Smith, Catherine (King's College London)
Background: Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments. [...]
2021 - 10.1111/bjd.19755
British journal of dermatology, Vol. 185 Núm. 1 (july 2021) , p. 80-90  
6.
9 p, 453.9 KB Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis : pooled analysis across six clinical trials / Strober, B. E. (Probity Medical Research) ; Gottlieb, Alice B (New York Medical College at Metropolitan Hospital) ; van de Kerkhof, P. C. M. (Radboud University Nijmegen Medical Centre) ; Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ; Bachelez, Hervé (Sorbonne Paris Cité Université Paris Diderot. Assistance Publique-Hôpitaux de Paris. Service de Dermatologie. Hôpital Saint-Louis) ; Chouela, E. (Universidad de Buenos Aires) ; Imafuku, S. (Department of Dermatology. Faculty of Medicine. Fukuoka University) ; Thaçi, Diamant (Universitätsklinikum Schleswig-Holstein (Alemanya)) ; Tan, H. (Pfizer Inc.) ; Valdez, H. (Pfizer Inc.) ; Gupta, P. (Pfizer Inc.) ; Kaur, M. (Pfizer Inc.) ; Frajzyngier, V. (Pfizer Inc.) ; Wolk, R. (Pfizer Inc.) ; Universitat Autònoma de Barcelona
Background: Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate-to-severe chronic plaque psoriasis. [...]
2019 - 10.1111/bjd.17149
British journal of dermatology, Vol. 180 Núm. 1 (january 2019) , p. 67-75  
7.
11 p, 1.5 MB The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis / Girolomoni, Giampiero (University of Verona) ; Strohal, Robert (Federal Academic Teaching Hospital of Feldkirch) ; Puig Sanz, Lluís (Universitat Autònoma de Barcelona) ; Bachelez, Hervé (Institut Imagine (Paris, França)) ; Barker, Jonathan (King's College London) ; Boehncke, Wolf-Henning (University of Geneva) ; Prinz, Joerg (University of Munich)
Psoriasis is a chronic, immune-mediated disease affecting more than 100 million people worldwide and up to 2. 2% of the population. The aetiology of psoriasis is thought to originate from an interplay of genetic, environmental, infectious and lifestyle factors. [...]
2017 - 10.1111/jdv.14433
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Issue 10 (October 2017) , p. 1616-1626  

Vegeu també: autors amb noms similars
9 Bachelez, Hervé
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.